Smartlab Europe

American Regent Recalls Batch of Calcium Gluconate Injections

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Periodontal Disease as a Modifiable Risk Factor in Systemic Conditions

Periodontal disease has long been viewed primarily as a...

How Pharma is Navigating EPR’s Split-Tier Reality in 2026 without Losing Regulatory Sterility

In 2026, the Pharmaceutical and Medical Device sectors face...

Novo Nordisk and Vivtex Sign Strategic Oral Biologics Deal

Novo Nordisk and Vivtex have formalised a collaboration aimed...
- Advertisement -

American Regent has initiated a voluntary nationwide recall of a batch of calcium gluconate injections due to the presence of silicone particulates.The recall affects lot number 1,006 of calcium gluconate injection, USP, 10%, 100mL. American Regent has distributed the injections, manufactured by Luitpold Pharmaceuticals, to wholesalers and distributors nationwide.Calcium gluconate is indicated to treat conditions such as hypocalcaemic tetany or hypocalcaemia, to relieve muscle cramping due to black widow spider bites, rickets, osteomalacia, lead colic and magnesium sulphate overdoses.The injection has also been employed to decrease capillary permeability in allergic conditions, non-thrombocytopenic purpura and exudative dermatoses such as dermatitis herpetiformis and for pruritus of eruptions caused by certain drugs.In hyperkalaemia, calcium gluconate may aid in antagonising the cardiac toxicity provided the patient is not receiving digitalis therapy.

Latest stories

Related stories

Periodontal Disease as a Modifiable Risk Factor in Systemic Conditions

Periodontal disease has long been viewed primarily as a...

How Pharma is Navigating EPR’s Split-Tier Reality in 2026 without Losing Regulatory Sterility

In 2026, the Pharmaceutical and Medical Device sectors face...

Novo Nordisk and Vivtex Sign Strategic Oral Biologics Deal

Novo Nordisk and Vivtex have formalised a collaboration aimed...

Pharmaceutical and Holistic Therapies: Exploring Their Role in Effective Addiction Recovery

Addiction recovery has evolved into a multidisciplinary clinical domain...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »